Patents by Inventor Ozkan Yalkinoglu

Ozkan Yalkinoglu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11149089
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: October 19, 2021
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
  • Publication number: 20190119393
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: October 2, 2018
    Publication date: April 25, 2019
    Applicant: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
  • Patent number: 10138302
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: November 27, 2018
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
  • Publication number: 20150050268
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: September 24, 2012
    Publication date: February 19, 2015
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Ozkan Yalkinoglu
  • Publication number: 20140212417
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: September 24, 2012
    Publication date: July 31, 2014
    Applicant: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
  • Publication number: 20140194318
    Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 10, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Õzkan Yalkinoglu, Gerhard König, Denis F. Hochstrasser, Jean-Charles Sanchez, Odile Carrette
  • Patent number: 8772042
    Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: July 8, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Özkan Yalkinoglu, Gerhard König, Denis Francois Hochstrasser, Jean-Charles Sanchez, Odile Carrette
  • Publication number: 20120016205
    Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.
    Type: Application
    Filed: May 2, 2011
    Publication date: January 19, 2012
    Applicant: BAYER HEALTHCARE AG
    Inventors: Õzkan Yalkinoglu, Gerhard Kõnig, Denis Francois Hochstrasser, Jean-Charles Sanchez, Odile Carrette
  • Patent number: 7202243
    Abstract: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: April 10, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Martin Hendrix, David Brückner, Arno Friedl, Irene Gerlach, Volker Hinz, Jörg Keldenich, Frank Mauler, Maria Niewöhner, legal representative, Dagmar Karthaus, Karl-Heinz Schlemmer, Adrian Tersteegen, Özkan Yalkinoglu, Ulrich Niewöhner, deceased
  • Publication number: 20060240561
    Abstract: A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.
    Type: Application
    Filed: August 11, 2003
    Publication date: October 26, 2006
    Inventors: Ozkan Yalkinoglu, Gerhard Konig, Denis Hochstrasser, Jean-Charles Sanchez, Odile Carrette
  • Publication number: 20060166992
    Abstract: The invention relates to new heterocyclically substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.
    Type: Application
    Filed: June 25, 2003
    Publication date: July 27, 2006
    Applicant: Bayer Healthcare A G
    Inventors: Martin Hendrix, David Bruckner, Arno Friedl, Irene Gerlach, Volker Hinz, Jorg Keldenich, Frank Mauler, Ulrich Niewohner, Maria Niewohner, Dagmar Karthaus, Karl-Heinz Schlemmer, Adrian Tersteeger, Ozkan Yalkinoglu
  • Publication number: 20060166993
    Abstract: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.
    Type: Application
    Filed: June 25, 2003
    Publication date: July 27, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Martin Hendrix, David Bruckner, Arno Friedl, Irene Gerlach, Volker Hinz, Jorg Keldenich, Frank Mauler, Ulrich Niewohner, Maria Niewohner, Dagmar Karthaus, Karl-Heinz Schlemmer, Adrian Tersteegen, Ozkan Yalkinoglu
  • Patent number: 5935983
    Abstract: The phenylcyclohexylcarboxamides, some of which are known, are suitable as active compounds in medicaments, in particular in medicaments for the treatment of restenosis.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: August 10, 1999
    Assignee: Bayer Aktiengesellschaft
    Inventors: Matthias Muller-Gliemann, Ulrich Muller, Martin Beuck, Siegfried Zaiss, Christoph Gerdes, Anke Domdey-Bette, Rudi Grutzmann, Stefan Lohmer, Stefan Wohlfeil, Ozkan Yalkinoglu, James Elting, Dirk Denzer
  • Patent number: 5627285
    Abstract: Sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be prepared by reacting sulphonylbenzyl-substituted aldehydes with appropriate CH-acidic compounds and then dehydrating.The sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be used in medicaments, in particular for the treatment of high blood pressure and atherosclerosis.
    Type: Grant
    Filed: September 6, 1995
    Date of Patent: May 6, 1997
    Assignee: Bayer Aktiengesellschaft
    Inventors: Rudolf Hanko, J urgen Dressel, Peter Fey, Walter H ubsch, Thomas Kr amer, Ulrich E. M uller, Matthias M uller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu
  • Patent number: 5607962
    Abstract: Substituted indole derivatives are prepared by reacting appropriate carboxylic acids, if appropriate in the presence of auxiliaries, with appropriate amines. The substituted indole derivatives are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and restenosis.
    Type: Grant
    Filed: January 25, 1996
    Date of Patent: March 4, 1997
    Assignee: Bayer Aktiengesellschaft
    Inventors: Matthias M uller-Gliemann, Ulrich M uller, Martin Beuck, Siegfried Zaiss, Christoph Gerdes, Anke Domdey-Bette, Rudi Gr utzmann, Stefan Lohmer, Stefan Wohlfeil, Ozkan Yalkinoglu, James Elting, Dirk Denzer
  • Patent number: 5475016
    Abstract: Sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be prepared by reacting sulphonylbenzyl-substituted aldehydes with appropriate CH-acidic compounds and then dehydrating.The sulphonylbenzyl-substituted imidazolylpropenoic acid derivatives can be used in medicaments, in particular for the treatment of high blood pressure and atherosclerosis.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: December 12, 1995
    Assignee: Bayer Aktiengesellschaft
    Inventors: Rudolf Hanko, Jurgen Dressel, Peter Fey, Walter Hubsch, Thomas Kramer, Ulrich E. Muller, Matthias Muller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu
  • Patent number: 5420149
    Abstract: Imidazolyl-substituted phenylacetic acid derivatives are prepared by first reacting suitably substituted phenylacetic acid with imidazoles and subsequently converting the product into an amide. The compounds can be employed as active compounds in medicaments, in particular for treating hypertension and atherosclerosis.
    Type: Grant
    Filed: March 3, 1993
    Date of Patent: May 30, 1995
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich E. Muller, Matthias Muller-Gliemann, Jurgen Dressel, Peter Fey, Rudolf Hanko, Walter Husch, Thomas Kramer, Martin Beuck, Stanislav Kazda, Stefan Wohlfeil, Ozkan Yalkinoglu, Andreas Knorr, Johannes-Peter Stasch, Ulrich Niewohner
  • Patent number: 5364942
    Abstract: Sulphonylbenzyl-substituted imidazopyridines can be prepared by reacting correspondingly substituted imidazopyridines with sulphonylbenzyl compounds. The sulphonylbenzyl-substituted imidazopyridines can be employed as active compounds in medicaments, in particular for the treatment of hypertension and atherosclerosis.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: November 15, 1994
    Assignee: Bayer Aktiengesellschaft
    Inventors: Rudolf Hanko, Jurgen Dressel, Peter Fey, Walter Hubsch, Thomas Kramer, Ulrich E. Muller, Matthias Muller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu
  • Patent number: 5352687
    Abstract: Substituted phenylacetamides can be prepared by reaction of appropriately substituted phenylacetic acids with imidazoles and subsequent amidation. The substituted phenylacetic acid derivatives can be employed in medicaments for the treatment of high blood pressure and atherosclerosis.
    Type: Grant
    Filed: March 3, 1993
    Date of Patent: October 4, 1994
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ulrich E. Muller, Matthias Muller-Gliemann, Jurgen Dressel, Peter Fey, Rudolf Hanko, Walter Hubsch, Thomas Kramer, Martin Beuck, Stanislav Kazda, Stefan Wohlfeil, Ozkan Yalkinoglu, Andreas Knorr, Johannes-Peter Stasch
  • Patent number: 5318980
    Abstract: Sulphonylbenzyl-substituted imidazoles can be prepared by first reacting imidazolylaldehydes with sulphonylbenzyl compounds and then oxidising or reducing the aldehyde function in the customary manner.The sulphonylbenzyl-substituted imidazoles can be used as active compounds in medicaments.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: June 7, 1994
    Assignee: Bayer Aktiengesellschaft
    Inventors: Rudolf Hanko, Jurgen Dressel, Peter Fey, Walter Hubsch, Thomas Kramer, Ulrich E. Muller, Matthias Muller-Gliemann, Martin Beuck, Stanislav Kazda, Claudia Hirth-Dietrich, Andreas Knorr, Johannes-Peter Stasch, Stefan Wohlfeil, Ozkan Yalkinoglu